Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1578358rdf:typepubmed:Citationlld:pubmed
pubmed-article:1578358lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0085979lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0042523lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0056506lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0071074lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0178987lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0936268lld:lifeskim
pubmed-article:1578358lifeskim:mentionsumls-concept:C0599473lld:lifeskim
pubmed-article:1578358pubmed:issue2lld:pubmed
pubmed-article:1578358pubmed:dateCreated1992-6-5lld:pubmed
pubmed-article:1578358pubmed:abstractTextThe effects of the potassium channel activators, cromakalim, BRL 38227 and pinacidil, and the calcium antagonist, verapamil, have been compared against various spasmogens on airway responses in vitro and in vivo in the guinea pig and also in human isolated bronchi. In guinea pig tracheal spirals, potassium channel activators generally had a greater inhibitory effect than verapamil against tone induced by a wide range of spasmogens (spontaneous, 5-hydroxytryptamine, leukotriene D4, prostaglandin E2). The potassium channel activators had very little effect against potassium chloride- and carbachol-induced tone in guinea pig tracheal spirals [e.g., cromakalim (20 microM) induced relaxations of 0.21 +/- 0.03 (relative to an isoprenaline maximum = 1.0, mean +/- S.E.M.) against carbachol, compared to 0.77 +/- 0.03 against histamine]. In vivo, the potassium channel activators prevented histamine and 5-hydroxytryptamine-induced bronchoconstrictions, but had little inhibitory effect against acetylcholine. In contrast, in human bronchi, cromakalim was capable of inducing powerful concentration-dependent relaxations against carbachol-induced tone [cromakalim (20 microM) induced relaxations of 0.77 +/- 0.09 (relative to isoprenaline = 1.0, mean +/- S.E.M.) against carbachol, compared to 0.95 +/- 0.04 against histamine]. In human bronchi, all the inhibitory agents were more potent and more effective, except that verapamil did not have an increased maximum response. We conclude that potassium channel activators should be effective at relaxing contractions induced by a wide range of spasmogens in man.lld:pubmed
pubmed-article:1578358pubmed:languageenglld:pubmed
pubmed-article:1578358pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:citationSubsetIMlld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1578358pubmed:statusMEDLINElld:pubmed
pubmed-article:1578358pubmed:monthMaylld:pubmed
pubmed-article:1578358pubmed:issn0022-3565lld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:BonoGGlld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:TaylorJ FJFlld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:BuckleD RDRlld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:TaylorS GSGlld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:ArchJ RJRlld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:ShawD JDJlld:pubmed
pubmed-article:1578358pubmed:authorpubmed-author:WareJ RJRlld:pubmed
pubmed-article:1578358pubmed:issnTypePrintlld:pubmed
pubmed-article:1578358pubmed:volume261lld:pubmed
pubmed-article:1578358pubmed:ownerNLMlld:pubmed
pubmed-article:1578358pubmed:authorsCompleteYlld:pubmed
pubmed-article:1578358pubmed:pagination429-37lld:pubmed
pubmed-article:1578358pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:meshHeadingpubmed-meshheading:1578358-...lld:pubmed
pubmed-article:1578358pubmed:year1992lld:pubmed
pubmed-article:1578358pubmed:articleTitleThe inhibitory effects of cromakalim and its active enantiomer BRL 38227 against various agonists in guinea pig and human airways: comparison with pinacidil and verapamil.lld:pubmed
pubmed-article:1578358pubmed:affiliationSmithKline Beecham Pharmaceuticals, Biosciences Research Centre, Epsom, Surrey, England.lld:pubmed
pubmed-article:1578358pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1578358pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1578358lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1578358lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1578358lld:pubmed